Edition:
United States

Verastem Inc (VSTM.OQ)

VSTM.OQ on NASDAQ Stock Exchange Global Market

3.90USD
4:00pm EDT
Change (% chg)

$-0.25 (-6.02%)
Prev Close
$4.15
Open
$4.13
Day's High
$4.20
Day's Low
$3.88
Volume
143,770
Avg. Vol
242,563
52-wk High
$5.71
52-wk Low
$1.07

Chart for

About

Verastem, Inc. is a biopharmaceutical company. The Company is focused on discovering and developing drugs to improve outcomes for patients with cancer. The Company operates in the segment of developing drugs for the treatment of cancer. The Company's advanced product candidates are VS 6063, VS 4718 and VS 5584. The Company's... (more)

Overall

Beta: 2.21
Market Cap(Mil.): $153.52
Shares Outstanding(Mil.): 36.99
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 89.64 16.86
EPS (TTM): -- -- --
ROI: -- 2.40 11.22
ROE: -- 3.29 15.09

BRIEF-Verastem makes milestone payment to Infinity Pharmaceuticals

* Verastem pays milestone payment to Infinity Pharmaceuticals

Oct 17 2017

Verastem's blood cancer drug succeeds in late-stage trial

Verastem Inc said on Wednesday its drug to treat some types of blood cancer met the main goal of a late-stage study, sending the U.S. drug developer's shares up as much as 44.5 percent.

Sep 06 2017

UPDATE 2-Verastem's blood cancer drug succeeds in late-stage trial

* Drug could rake in >$400 mln within 5 yrs of launch -analyst

Sep 06 2017

BRIEF-Verastem expands duvelisib development program to include peripheral T-cell lymphoma

* Verastem expands duvelisib development program to include peripheral T-cell lymphoma

Sep 06 2017

RPT-Verastem's blood cancer drug succeeds in late-stage trial

Sept 6 Verastem Inc said on Wednesday its drug to treat certain types of blood cancer met the main goal of a late-stage study.

Sep 06 2017

RPT-Verastem's blood cancer drug succeeds in late-stage trial

Sept 6 Verastem Inc said on Wednesday its drug to treat certain types of blood cancer met the main goal of a late-stage study.

Sep 06 2017

BRIEF-Verastem announces positive top-line data from the pivotal phase 3 Duo study

* Verastem announces positive top-line data from the pivotal phase 3 Duo study in relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma

Sep 06 2017

Verastem's blood cancer drug succeeds in late-stage trial

Sept 6 Verastem Inc said on Wednesday its drug to treat certain types of blood cancer met the main goal of a late-stage study.

Sep 06 2017

BRIEF-Ridgeback Capital Investments reports 7.7 pct passive stake in Verastem

* Ridgeback Capital Investments Lp reports a 7.7 percent passive stake in Verastem inc as of July 10, 2017 - sec filing Source text for Eikon: Further company coverage:

Jul 20 2017

BRIEF-Verastem names Julie B. Feder as chief financial officer

* Verastem Inc - ‍feder joins Verastem from Clinton Health Access Initiative, Inc​ Source text for Eikon: Further company coverage:

Jul 11 2017

Earnings vs. Estimates